Methods for treating emotional cognitive disconnect

Abstract

The present invention relates to the treatment of refractory Emotional Cognitive Disconnect (ECD) through a combination of pharmaceutical agents and therapy. Individual patients are treated with a combination of magnesium, inositol, and N-acetylcysteine along with Vitamin E, Vitamin C, zinc, biotin, alphalipoic acid and lysine as required. The compositions may be administered sequentially or simultaneously in any order and may be formulated in singular or combinatorial dosage forms.

The invention claimed is: 
     
       1. A method of treating Emotional Cognitive Disconnect in treatment-resistant individuals, comprising:
 identifying an individual suffering from Emotional Cognitive Disconnect, wherein an individual presenting with:
 separation of affect/emotion and cognition, 
 inability to self-observe the separation and account for it, 
 inability to combine affects and cognitions, and 
 repeated inability of the individual to listen when affect/emotion and cognitions are combined by someone else, 
 
 is identified as suffering from Emotional Cognitive Disconnect; 
 administering daily to the individual a first composition consisting of 250 mg of magnesium per day for a first month; 
 evaluating the individual weekly for tolerance of the first composition; 
 monitoring the individual weekly for increased emotional processing, wherein increased emotional processing is a decrease in the separation of affect/emotion and cognition; 
 determining the tolerance for the first composition; and 
 while continuing administration of the first composition, sequentially administering daily a second composition comprising about 250 mg of inositol, wherein a level of inositol is increased by about 250 mg per day for a second, third, and fourth month. 
 
     
     
       2. The method of  claim 1 , wherein the inositol is increased to about 18000 mg per day. 
     
     
       3. The method of  claim 1 , further comprising sequential daily administration of a third composition comprising about 500 mg to about 1000 mg per day of N-acetylcysteine in combination with the first composition and the second composition for a fifth and sixth month. 
     
     
       4. The method of  claim 3 , further comprising sequential administration of a fourth composition comprising about 50 mg of zinc. 
     
     
       5. The method of  claim 4 , wherein the first, second, third, and fourth compositions are administered up to a total of 24 months. 
     
     
       6. The method of  claim 1 , wherein the individual is evaluated by clinical observation. 
     
     
       7. The method of  claim 1 , wherein tolerance for the first composition is determined by an absence of stomach upset, nausea, vomiting, or diarrhea. 
     
     
       8. A method of restoring parasympathetic functioning comprising:
 identifying an individual suffering from Emotional Cognitive Disconnect, wherein an individual presenting with:
 separation of affect/emotion and cognition, 
 inability to self-observe the separation and account for it, 
 inability to combine affects and cognitions, and 
 repeated inability of the individual to listen when affect/emotion and cognitions are combined by someone else, 
 
 is identified as suffering from Emotional Cognitive Disconnect; 
 administering daily to the individual in need of restoration a first composition consisting of 250 mg of magnesium for a first month; 
 evaluating the individual weekly for tolerance of the first composition; 
 monitoring the individual weekly for increased parasympathetic functioning; 
 determining the tolerance for the first composition; and 
 while continuing administration of the first composition, sequentially administering daily a second composition comprising about 250 mg of inositol, wherein a level of inositol is increased by about 250 mg per day for a second, third, and fourth month. 
 
     
     
       9. The method of  claim 8 , wherein the inositol is increased to about 18000 mg per day. 
     
     
       10. The method of  claim 8 , wherein increased parasympathetic functioning is evaluated using one or more methods selected from a Valsalva maneuver, respiratory arrhythmia, isometric handgrip test, cold pressor test, mental arithmetic, orthostatic test, mental arithmetic test, head up tilt test, baroreflex sensitivity testing, analysis of heart rate variability, measurements of noradrenaline concentration, microneurography, thermoregulatory sweat test, sympathetic skin response, and quantitative sudomotor axon reflex test. 
     
     
       11. The method of  claim 10 , further comprising sequential daily administration of a third composition comprising about 500 mg to about 1000 mg per day of N-acetylcysteine in combination with the first composition and the second composition for a fifth and sixth month. 
     
     
       12. The method of  claim 11 , further comprising sequential administration of a fourth composition comprising about 50 mg of zinc. 
     
     
       13. The method of  claim 12 , wherein the first, second, third, and fourth compositions are administered up to a total of 24 months. 
     
     
       14. The method of  claim 13 , wherein the individual is monitored by clinical observation and by using at least one clinical scale selected from a Beck Depression Inventory, or a Cage Questionnaire for the testing of Opioid Dependence of Sexual Abuse victims with chronic pain.